This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Management of myoclonic seizures

Authoring team

Pharmacological treatment of myoclonic seizures

First-line treatment in children, young people and adults with myoclonic seizures

  • sodium valproate should be offered as first-line treatment to children, young people and adults with newly diagnosed myoclonic seizures, unless it is unsuitable. Follow the MHRA safety advice on sodium valproate
  • levetiracetam or topiramate should be considered if sodium valproate is unsuitable or not tolerated. Be aware that topiramate has a less favourable side-effect profile than levetiracetam and sodium valproate. Follow the MHRA safety advice on sodium valproate

Adjunctive treatment in children, young people and adults with myoclonic seizures

  • levetiracetam, sodium valproate or topiramate should be offered as adjunctive treatment to children, young people and adults with myoclonic seizures if first-line treatments are ineffective or not tolerated. Follow the MHRA safety advice on sodium valproate

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.